Lupin Among Fastest to Climb S&P Global ESG Rankings in Indian Pharma

Lupin has one of the quickest increases in the S&P Global ESG scores among pharmaceutical companies in India. Lupin Limited, a leading pharmaceutical company, reported an increase in its S&P Global ESG scores from 69 to 76, surpassing the industry average of 30 in the pharmaceutical sector. The company has shown ongoing and stable growth in its Environment, Social, and Governance (ESG) performance, highlighting its dedication to all areas of business.

Lupin's S&P Global ESG Score has been tracked for the past four years. Lupin's strategy is centered around a robust Sustainability framework, which is seamlessly integrated into every aspect of its business operations. Lupin is setting the stage for a more sustainable and fair future by speeding up its move towards net-zero emissions, improving social impact, and maintaining top governance standards.

Commenting on the achievement, Ramesh Swaminathan, Executive Director, Global CFO and Head – API Plus SBU, Lupin said, “We have made significant progress in our Environmental, Social, and Governance goals over the last four years. The S&P score reaffirms our commitment to prioritizing sustainability and creating impactful and sustainable healthcare solutions that benefit our patients and our communities worldwide.”

Lupin's primary focuses on ESG include environmental stewardship, employee well-being, supply chain sustainability, and patient-centric innovation.